Zydus Lifesciences Limited Cash Flow Conversion Efficiency
Zydus Lifesciences Limited cash flow conversion efficiency. Based on the latest financial reports, Zydus Lifesciences Limited (ZYDUSLIFE) has a cash flow conversion efficiency ratio of 0.018x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs3.68 Billion ≈ $39.84 Million USD) by net assets (Rs209.41 Billion ≈ $2.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zydus Lifesciences Limited (2004–2025)
Cash flow conversion efficiency of Zydus Lifesciences Limited from 2004 to 2025. This chart illustrates how Zydus Lifesciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ZYDUSLIFE stock price for real-time trading data and today's change.
Zydus Lifesciences Limited Cash Flow Conversion Ratio Explained
Zydus Lifesciences Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zydus Lifesciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zydus Lifesciences Limited ranked by their cash flow conversion efficiency. Also see market value of Zydus Lifesciences Limited for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LTIMindtree Limited
NSE:LTM
|
0.150x |
|
China Satellite Communications Co Ltd
SHG:601698
|
0.017x |
|
Huazhu Group Ltd
NASDAQ:HTHT
|
0.237x |
|
EIFFAGE S.A.ADR 1/5/EO 4
F:EF30
|
N/A |
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
0.090x |
|
TKO Group Holdings, Inc.
NYSE:TKO
|
0.081x |
|
Mr. Cooper Group Inc
NASDAQ:COOP
|
0.058x |
|
Hasbro Inc
NASDAQ:HAS
|
0.501x |
Annual Cash Flow Conversion Efficiency for Zydus Lifesciences Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Zydus Lifesciences Limited from 2004 to 2025. Review Zydus Lifesciences Limited (ZYDUSLIFE) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs263.58 Billion ≈ $2.85 Billion |
Rs67.77 Billion ≈ $732.87 Million |
0.257x | +77.78% |
| 2024-03-31 | Rs221.02 Billion ≈ $2.39 Billion |
Rs31.96 Billion ≈ $345.67 Million |
0.145x | +5.89% |
| 2023-03-31 | Rs196.88 Billion ≈ $2.13 Billion |
Rs26.89 Billion ≈ $290.78 Million |
0.137x | +23.67% |
| 2022-03-31 | Rs190.54 Billion ≈ $2.06 Billion |
Rs21.04 Billion ≈ $227.55 Million |
0.110x | -49.93% |
| 2021-03-31 | Rs149.30 Billion ≈ $1.61 Billion |
Rs32.93 Billion ≈ $356.13 Million |
0.221x | +3.10% |
| 2020-03-31 | Rs117.10 Billion ≈ $1.27 Billion |
Rs25.05 Billion ≈ $270.95 Million |
0.214x | -13.31% |
| 2019-03-31 | Rs116.79 Billion ≈ $1.26 Billion |
Rs28.82 Billion ≈ $311.71 Million |
0.247x | +139.88% |
| 2018-03-31 | Rs89.36 Billion ≈ $966.34 Million |
Rs9.19 Billion ≈ $99.42 Million |
0.103x | -45.75% |
| 2017-03-31 | Rs71.16 Billion ≈ $769.58 Million |
Rs13.49 Billion ≈ $145.94 Million |
0.190x | -47.81% |
| 2016-03-31 | Rs54.87 Billion ≈ $593.43 Million |
Rs19.94 Billion ≈ $215.62 Million |
0.363x | +61.65% |
| 2015-03-31 | Rs44.20 Billion ≈ $478.06 Million |
Rs9.94 Billion ≈ $107.45 Million |
0.225x | -9.20% |
| 2014-03-31 | Rs35.83 Billion ≈ $387.52 Million |
Rs8.87 Billion ≈ $95.93 Million |
0.248x | +28.35% |
| 2013-03-31 | Rs30.64 Billion ≈ $331.34 Million |
Rs5.91 Billion ≈ $63.90 Million |
0.193x | +2.37% |
| 2012-03-31 | Rs26.64 Billion ≈ $288.10 Million |
Rs5.02 Billion ≈ $54.28 Million |
0.188x | -37.02% |
| 2011-03-31 | Rs22.38 Billion ≈ $242.07 Million |
Rs6.70 Billion ≈ $72.41 Million |
0.299x | -21.11% |
| 2010-03-31 | Rs16.68 Billion ≈ $180.36 Million |
Rs6.32 Billion ≈ $68.39 Million |
0.379x | +118.22% |
| 2009-03-31 | Rs12.58 Billion ≈ $136.05 Million |
Rs2.19 Billion ≈ $23.64 Million |
0.174x | +1.43% |
| 2008-03-31 | Rs10.82 Billion ≈ $116.97 Million |
Rs1.85 Billion ≈ $20.04 Million |
0.171x | -40.22% |
| 2007-03-31 | Rs8.80 Billion ≈ $95.14 Million |
Rs2.52 Billion ≈ $27.26 Million |
0.287x | +80.46% |
| 2006-03-31 | Rs7.00 Billion ≈ $75.66 Million |
Rs1.11 Billion ≈ $12.02 Million |
0.159x | -58.87% |
| 2005-03-31 | Rs5.93 Billion ≈ $64.17 Million |
Rs2.29 Billion ≈ $24.78 Million |
0.386x | -11.46% |
| 2004-03-31 | Rs5.36 Billion ≈ $58.01 Million |
Rs2.34 Billion ≈ $25.30 Million |
0.436x | -- |
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more